Currently, there are no absolute contraindications to semaglutide use based solely on the presence of an autoimmune condition
Clinical trials have shown that over 90% of participants completed their Wegovy treatment programmes despite experiencing symptoms, which means that the challenges you could face are surmountable when you know how and have the right level of support
Typical limitations for a real-world study also apply for the individual PIONEER REAL studies, where limitations are described in more detail [18,19,20,21,22]
numbers below the panels are the number of participants contributing to the mean
10.1016/j.canlet.2017.12.003 81 WangL.BergerN
Patients also want a setting where they feel informed and supported throughout the process